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Abstract
Protein import into mitochondria is facilitated by translocases within the outer and the inner mitochondrial membranes
that are dedicated to a highly specific subset of client proteins. The mitochondrial carrier translocase (TIM22 complex)
inserts multispanning proteins, such as mitochondrial metabolite carriers and translocase subunits (TIM23, TIM17A/B and
TIM22), into the inner mitochondrial membrane. Both types of substrates are essential for mitochondrial metabolic function
and biogenesis. Here, we report on a subject, diagnosed at 1.5 years, with a neuromuscular presentation, comprising
hypotonia, gastroesophageal reflux disease and persistently elevated serum and Cerebrospinal fluid lactate (CSF). Patient
fibroblasts displayed reduced oxidative capacity and altered mitochondrial morphology. Using trans-mitochondrial cybrid
cell lines, we excluded a candidate variant in mitochondrial DNA as causative of these effects. Whole-exome sequencing
identified compound heterozygous variants in the TIM22 gene (NM 013337), resulting in premature truncation in one allele
(p.Tyr25Ter) and a point mutation in a conserved residue (p.Val33Leu), within the intermembrane space region, of the TIM22
protein in the second allele. Although mRNA transcripts of TIM22 were elevated, biochemical analyses revealed lower levels
of TIM22 protein and an even greater deficiency of TIM22 complex formation. In agreement with a defect in carrier
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translocase function, carrier protein amounts in the inner membrane were found to be reduced. This is the first report of
pathogenic variants in the TIM22 pore-forming subunit of the carrier translocase affecting the biogenesis of inner
mitochondrial membrane proteins critical for metabolite exchange.
Introduction
Mitochondria represent metabolic core units and signaling hubs
of eukaryotic cells. For their central role in energy production
through oxidative phosphorylation, the inner membrane has to
maintain a proton gradient (pH) that drives Adenosine triphos-
phate (ATP) production in the matrix. Hence, the transport of
metabolites into and out of mitochondria is mediated by ded-
icated transport systems that utilize the proton gradient as a
driving force, but maintain the pH. This is true for metabolite
carriers and also for protein transport machineries.
Mitochondria import the vast majority of proteins from the
cytosol, while only 13 proteins are mitochondrial-encoded. The
translocase of the outer mitochondrial membrane (TOM com-
plex) represents the general entry port into mitochondria for
precursor proteins. Upon passage through the TOM complex,
precursors are segregated to engage with dedicated translocases
in the outer membrane, the intermembrane space (IMS) and the
inner membrane in a signal-specific manner (1–4). The carrier
translocase (TIM22 complex) mediates the transport of carrier
proteins for inner membrane insertion. These precursors utilize
internal targeting signals for transport (5,6). In addition to the six
transmembrane span containing carrier proteins, TIM22 cargoes
also include the four transmembrane span containing channel-
forming subunits of the TIM23 complex (TIM23 and TIM17A/B)
and the TIM22 protein itself (7–12).
The TIM22 complex is comprised of a central twin-pore form-
ing unit, made up of two channels formed by the TIM22 protein
(13,14). Additional components include the conserved TIM10B
and the metazoan-specific subunits, TIM29 and acylglycerol
kinase (AGK) (7–10,15). Together, these proteins constitute a
complex of ∼440 kDa. Both TIM29 and AGK are required for
the stability and import competence of the translocase (7,8).
Two conserved soluble hexameric rings, made up of TIM9 and
TIM10A as well as TIM8A and TIM13, respectively, reside in the
mitochondrial IMS and are responsible for guiding the precursor
from the TOM complex to the TIM22 complex (16–19). Upon
docking to the TIM22 complex, the precursor is released into the
TIM22 channel and its insertion into the membrane is driven by
the mitochondrial membrane potential ψ (13,20) (Fig. 1).
The function of the TIM22 complex is conserved from yeast
to human and loss of TIM22 in yeast is lethal (14,21). This is not
surprising, given the role of TIM22 for not only the insertion of
metabolite carrier proteins, but also for the biogenesis of the
TIM23 complex,which is responsible for the import of precursors
with N-terminal presequences that represent ∼60% of the mito-
chondrial proteome (5,22). As such, disease-causing mutations
in components of the carrier translocase are extremely rare (23).
Recently, AGK, which had been implicated in Sengers syndrome,
was identified as a component of the TIM22 complex. AGK is
a bifunctional protein. In addition to being a carrier translo-
case subunit, AGK functions as lipid kinase in mitochondrial
lipid metabolism. Its role in the carrier translocase is appar-
ently independent of its kinase function and could explain the
metabolic defects observed in patients with Sengers syndrome
(9,10). Accordingly, both functions contribute to the observed
mitochondrial pathology. Moreover, pathogenic variants have
been reported in TIM8A, associated with deafness-dystonia-
Figure 1. Composition of human TIM22 complex and mechanism of action.
The TIM22 complex is comprised of the central twin-pore forming unit TIM22,
in addition to TIM10B and the metazoan specific subunits, TIM29 and AGK.
A soluble hexameric ring, made up of TIM9 and TIM10A and present in the
IMS, guides precursors (carrier proteins or TIM22, TIM23, TIM17A/B) from the
TOM complex to the TIM22 complex. Upon docking to the TIM22 complex, the
precursor is released into the TIM22 channel and its insertion into themembrane
is driven by the mitochondrial membrane potential ψ.
optic neuronopathy syndrome, also known asMohr–Tranebjaerg
syndrome (24,25). However, the substrate spectrum and the role
of TIM8A in protein transport in human remain poorly defined.
Here we report a patient with gastroesophageal reflux
disease, hypotonia and persistently elevated lactate levels
with biochemical evidence of mitochondrial dysfunction in
fibroblasts. Whole-exome sequencing identified compound
heterozygous variants in the TIM22 gene, encoding the TIM22
channel protein of the carrier translocase. Despite elevated
expression of TIM22 mRNA, biochemical analyses demonstrate
severely compromised levels of the TIM22 protein and, con-
comitantly, of the TIM22 complex. We found a reduced amount
of tested carrier proteins, which are imported by the TIM22
complex, in the inner mitochondrial membrane. Our analyses
link mutations in the core subunit of the carrier translocase to
the complex pathology of a human disorder through a defect in
the transport of metabolite carriers.
Results
Case presentation
We investigated the molecular basis of a presumed mitochon-
drial disorder in a 10-year-old British female of mixed ethnic
background, previously reported in the literature (26). She
is the third child of a healthy, non-consanguineous parents,
with no familial history of neurological disease apart from
epilepsy in amaternal aunt. Intrauterine growth retardationwas
observed at 32 weeks of pregnancy. At birth, she had a low birth
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Figure 2. Patient fibroblasts exhibit reduced mitochondrial fitness. (A) Cell counts of control and patient cells after 3 days of growth on glucose or galactose (Standard
error of the mean (SEM), n = 3). (B) Mitochondrial network of a representative control and patient fibroblast cell, stained with MitoTracker and DAPI. Scale bar = 15 μm.
(C) Real-time respirometry of patient and control cells; OCR. (D) SDS-PAGE and western blot analysis of OXPHOS subunits with indicated antibodies in control and
patient fibroblast lysates using β-actin as loading control. (E) blue native polyacrylamide gel electrophoresis (BN-PAGE) and western blot analysis of OXPHOS complexes
in solubilized mitochondria from control and patient fibroblasts using indicated antibodies. (F) In vivo labelling of mitochondrial translation products in control and
patient immortalized cells. Samples were analysed by SDS-PAGE, digital autoradiography and western blotting.
weight (2.33 kg) and below-average height (45 cm) and showed
reduced spontaneous movements and hypotonia. The subject
presented with feeding difficulties, gastroesophageal reflux with
projectile vomiting and acetabular dysplasia. Brain magnetic
resonance imaging at 8 months revealed a delay in white matter
myelination.She remainedproportionately small (height,weight
and head circumference all below the 0.4th centile) and weak
throughout childhood. Biochemical analyses revealed increased
lactate (4.2 mmol/L; normal controls, 0.5–2.2 mmol/L) and
creatine kinase (282 U/L; normal controls, 100–190 U/L) levels
in plasma and she underwent a diagnostic muscle biopsy on
suspicion of mitochondrial disease. This identified decreased
activities of respiratory chain complexes I, III and IVwith sparing
of complex II activity (26). Having excluded mitochondrial DNA
(mtDNA) rearrangements and a quantitative loss of mtDNA copy
number, full mtDNA sequencing revealed a rare homoplasmic
m.5514A>G mt-tRNATrp variant not present in >3000 human
mtDNA control sequences (26). The m.5514A>G transition
affects anA-U base pair in the acceptor stemofmt-tRNATrp, how-
ever, this position in the transfer RNA (tRNA) molecule shows
poor evolutionary conservation (26). The m.5514A>G variant
was homoplasmic in the blood from her clinically unaffected
mother, prompting further studies to assess pathogenicity
and the possible implications of this rare mtDNA variant at a
cellular level.
Assessment of mitochondrial function in patient
fibroblasts
To assess the cellular effects that underlie the mitochondrial
phenotype, primary fibroblasts of the patient and age-matched
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controls were obtained. First, to assay the capacity of the
oxidative phosphorylation (OXPHOS) system in patient cells,
we measured the growth rate of cells in glucose and galactose
medium for 3 days. In glucose medium, cells depend on
glycolysis, whereas in galactose medium, cells depend almost
exclusively on OXPHOS to produce the required amount
of ATP and maintain a physiological proliferation rate (27).
Surprisingly, patient-derived fibroblasts showed a similar growth
rate compared to those of the control (Fig. 2A). When the
mitochondrial network was analysed in fibroblast cells by
fluorescence microscopy in cells stained with MitoTracker,
patient cells displayed a partially fragmented mitochondrial
network when compared to controls (Fig. 2B). Next, we assessed
respiratory chain function—reported to be abnormal in patient
muscle—in fibroblasts, assessing oxygen consumption in intact
cells by real-time respirometry. Patient fibroblasts displayed a
lower oxygen consumption rate (OCR) during both basal and
uncoupled respiration (Fig. 2C). However, these differences were
much milder than those reported in other cases of multiple
respiratory chain deficiencies, such as the loss of the ribosome
assembly factor c7orf30 (leading to a combined complex I, III and
IV deficiency) (28), or in cells lacking the complex IV assembly
factor COA6 (complex I and IV defects) (29,30). In addition,
there was no obvious decrease in the steady-state protein
levels of OXPHOS subunits or of assembled complexes (Fig. 2D
and 2E). An assessment of the levels of mitochondrial-encoded
translation products using [35S] methionine showed that the
protein synthesis rates were similar in both control and patient
cells, indicating no significant mitochondrial translation defect
(Fig. 2E), unlike other reported pathological tRNA variants (31,32).
Thus, we concluded that, in contrast to skeletal muscle, the
patient fibroblasts showed only a mild mitochondrial OXPHOS
dysfunction and reduced integrity of themitochondrial network.
A nuclear genetic basis of the mitochondrial phenotype
To assess whether factors in the nuclear genetic back-
ground affect the phenotypic expression of the mitochondrial
m.5514A>G variant, we generated transmitochondrial cybrid
cells, fusing platelets from the patient and controls with
lung carcinoma cells (A549) lacking mtDNA (rho0). Sequencing
analysis confirmed the presence or absence of the m.5514A>G
variant in the obtained cell lines (Fig. 3A) that share an identical
nuclear genetic background. Assessment of mitochondrial
protein synthesis rates by [35S] methionine labelling failed to
show decreased mitochondrial translation in the mutant cybrid
cells (Fig. 3B). Defects in mitochondrial translation affect the
synthesis of core subunits of the OXPHOS system, prompting the
measurement of the enzymatic activity of cytochrome c oxidase
and levels of mitochondrial ATP in mutant cybrid cells. Cells
harbouring 100% m.5514A>G showed control levels of complex
IV enzyme activity and ATP levels (Fig. 3C and D). Taken together,
these analyses demonstrated that a different nuclear genetic
environment can complement the mitochondrial OXPHOS
phenotype and that the m.5514A>G variant was not responsible
for the mitochondrial phenotype.
Identification of compound heterozygous variants
in TIM22
To identify the underlying genetic defect, blood DNA from the
patient was subjected to whole-exome sequencing, followed
by previously described bioinformatics filtration for candi-
Figure 3. Anuclear genetic basis of themitochondrial phenotype. (A) Sequencing
electropherogram showing the presence or absence of the m.5514A>G in A549
cybrid cells. (B) In vivo labelling of mitochondrial translation products in control
and mutant cybrids. Samples were analysed by SDS-PAGE and autoradiography.
(C) Cytochrome c oxidase enzymatic activity, normalized by the enzymatic activ-
ity of CS, of mutant cybrid cells relative to control cybrids (Standard deviation
(STDEV), n = 3). (D) Levels of mitochondrial ATP in mutant cybrids compared to
control (STDEV, n = 6).
date coding or splicing variants that segregate in a manner
consistent with the segregation of the disease in the family
and incidence of the disorder in the general population (33).
Inspection of the candidate variant list for mitochondrial
genes revealed two heterozygous variants in the TIM22 gene
(NM 013337), encoding the core channel-forming subunit
of the carrier translocase of the inner mitochondrial mem-
brane. The identified variants—NM 013337.2:c.74C>A, TIM22:p.
Tyr25Ter and NM 013337.2:c.97G>C, TIM22:p.Val33Leu—had
not been previously associated with a disease (Fig. 4A). The
p.Tyr25Ter and p.Val33Leu variants have been previously
observed at population frequencies of ∼0.006% (7 of 115 100
individuals) and ∼0.4% (486 of 116 768 individuals), respectively,
among individuals of unknown disease status catalogued in
the ExAC database. No homozygous individuals have been
previously identified with the p.Tyr25∗ variant, whereas four
individuals of unknown disease status have been reported to
carry the p.Val33Leu variant in homozygosity (34). Due to the
essential role of TIM22 in mitochondrial protein biogenesis,
it is likely that homozygous variants are deleterious. Familial
segregation studies confirmed that the unaffected mother
carries the heterozygous p.Tyr25∗ variant and the father
is a carrier of the p.Val33Leu variant (Fig. 4B). Quantitative
polymerase chain reaction (PCR) measurements of TIM22
transcripts from the patient fibroblasts showed an increase in
TIM22 mRNA by almost 2-fold, compared to control fibroblasts
(Fig. 4C). Therefore, the patient’s phenotype is probably due
to a rare genetic event that combines the single effects of
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Figure 4. Identification of compound heterozygous variants in TIM22. (A) New mutations identified in the TIM22 gene locus. (B) Family pedigree showing patient and
known unaffected relatives carrying single heterozygous variants. Circle denotes female and square denotesmale familymembers. (C) Quantitative PCR of TIM22mRNA
levels in patient fibroblasts, relative to control fibroblasts (set to 1.0). TIM22 mRNA levels were normalized to HPRT (SEM, n = 3). (D) Amino acid sequence alignment of
the p.Val33Leu containing-segment of TIM22 in indicated organisms. (E) Position of variant p.Val33Leu according to the predicted topology of TIM22.
both variants. Whereas the p.Tyr25∗ is definitively pathogenic,
predicting loss of TIM22 protein expression, themolecular effect
of the p.Val33Leu variant on TIM22 function remains to be
determined. Indeed, valine 33 is highly conserved in higher
eukaryotes, whereas similar amino acids (like isoleucine or
methionine) are found inmore evolutionarily distant species like
Saccharomyces cerevisiae or Neurospora crassa (Fig. 4D). According
to the predicted topology of the TIM22 protein (35), the position
of valine 33 is located in the N-terminal segment, which resides
in the IMS before the first transmembrane span (Fig. 4E).
TIM22 p.Val33Leu destabilizes the carrier translocase
and affects metabolite carrier levels
To determine the effect of TIM22 p.Val33Leu on mitochon-
drial function, we assessed the integrity of the TIM22 com-
plex. N-Dodecyl-β-maltoside (DDM)-solubilized mitochondrial
membranes derived from either control or patient fibroblast
were separated by blue native polyacrylamide gel electrophore-
sis (PAGE) and analysed by western blotting. The human
TIM22 complex displays an apparent molecular mass of
∼440 kDa (7,8) and was detected in control mitochondria when
using antibodies directed against TIM22. Interestingly, patient
mitochondria displayed a drastically reduced TIM22 signal,
whereas complex V (ATP5B) and complex II (SDHA) were similar
in both samples (Fig. 5A). Re-expression of wild-type TIM22
in patient fibroblasts restored the TIM22 complex (Fig. 5B),
indicating that the amount of TIM22 or the Val to Leu exchange
affect assembly or stability of the translocase.
The human carrier translocase consists of the channel-
forming TIM22, TIM10B and twometazoan-specific components,
TIM29 and AGK. To understand if the reduction in fully
assembled complex in mutant mitochondria reflects only
decreased levels of TIM22, or if other components of the
translocase were also affected, we performed western blotting
analyses after sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). In mitochondria from patient
fibroblasts, TIM22 levels were decreased, as well as TIM29,
in accordance with previously published data showing that
the amounts of these two proteins are interdependent (8). On
the contrary, the levels of AGK remained similar in patient
mitochondria compared to the control mitochondria, probably
due to the second function of this enzyme in lipid metabolism
(9,10). In addition, the levels of the carrier translocase transport
substrate, ANT3 (ADP/ATP carrier), were clearly decreased in the
patient sample. Steady-state amounts of the inner membrane
translocase subunit, TIM23 (another known substrate of the
TIM22 complex), as well as presequence pathway proteins,
such as ATP5B, MIC60 and MITRAC12, remained similar to
the control (Fig. 5B). A semi-quantitative assessment of the
protein levels showed that at steady-state TIM22 p.Val33Leu
and TIM29 were reduced to ∼40% and ∼60% of wild type
(WT) level, respectively, in mitochondria from the patient
cells. ANT3 levels were also significantly decreased (∼60% of
WT) (Fig. 5C). In summary, we demonstrated that the TIM22
p.Val33Leu variant significantly reduced the levels of TIM22
and the structural component TIM29, resulting in a drastic
loss of the translocationmachinery. Concomitantly, steady-state
levels of carrier substrate proteins are reduced in mitochondria.
We speculate that the mitochondrial respiratory phenotype
and disrupted morphology observed in patient fibroblasts are
probably the result of an imbalance of metabolites inside
mitochondria, derived from impaired import and insertion of
carrier proteins to the inner membrane.
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Figure 5. The p.Val33Leu variant destabilizes the carrier translocase and affects metabolite carrier levels. (A) Isolated mitochondria from control and patient fibroblasts
were solubilized and resolved using BN-PAGE, followed by western blotting and detection using the indicated antibodies. (B) Patient immortalized fibroblast cells were
electroporated with wild-type TIM22. Mitochondria from these cells and from non-electroporated control and patient cells were isolated, solubilized and analysed by
BN-PAGE, followed by western blotting and detection using the indicated antibodies. (C) Isolated mitochondria from control and patient fibroblasts were subjected to
SDS-PAGE and western blotting. (D) Quantification of western blotting signals using infrared secondary antibodies in patient mitochondria compared to control and
normalized to the VDAC signal (SEM, n = 3).
Discussion
We report here a patient with a neuromuscular presentation of
mitochondrial disease and, what we consider may be, the first
described pathological variants in TIM22 as a cause ofMendelian
mitochondrial disease. In yeast, defects in the Tim22 protein,
the channel-forming subunit of the carrier translocase, impairs
cell viability. The human TIM22 protein shares 41% similarity
with its yeast counterpart (15) and it is likely that its function
remains essential in higher eukaryotes. Severe perturbations are
expected to result in embryonic lethality and this could explain
the lack of known pathological variants in TIM22 identified to
date. Therefore, the underlying defect in our patient is the result
of a genetic event, combining two rare variants in TIM22, one
that generates a premature stop codon (p.Tyr25∗) and a second
variant that produces a single amino acid change (p.Val33Leu).
Both genetic variants are present as single heterozygous changes
in unaffected parents of the patient, confirming carrier status.
We found that the pVal33Leu mutation of TIM22 disrupts
translocase complex formation and compromises levels of
metabolite carrier proteins within the inner membrane. Other
known substrates of the TIM22 complex are the components of
the presequence translocase TIM17A/B and TIM23. Surprisingly,
we didn’t observe a decreased level of TIM23 in patient mito-
chondria. However, both Sengers syndrome patient fibroblasts
harbouring AGK variants and HEK293 AGK knockout cells, where
the 440 kDa TIM22 dissociates into a smaller undefined complex,
failed to show significantly reduced import and assembly or
decreased levels of TIM23 (10). Recent quantitative analyses
of the abundance of mitochondrial proteins in yeast showed
that in fully respiring yeast cells (grown on a non-fermentable
carbon source), components of the translocases of the inner
membrane (TIM22 and TIM23) have relatively low abundance
within mitochondria (∼11 400 copies/cell of Tim23 and ∼1050
copies of Tim22), in comparison with, for example, metabolic
enzymes (Aco1 ∼152 000 copies/cell), metabolite carriers (Aac1
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∼27 500 copies/cell) or subunits of the respiratory chain (Cox4
∼91 700 copies/cell) (36). This demonstrates that the import of
substrates through the inner membrane is extremely efficient
and, therefore, it is probable that the lower steady-state levels
of TIM22 complex in patient mitochondria are still capable of
importing andmaintaining physiological levels of critical cargos.
It could also be speculated that there is an additional layer of
regulation of the carrier translocase that preferentially supports
the biogenesis of certain substrates, such as TIM23 channel
components, but this remains to be determined.
Interestingly, protein levels of TIM22 were significantly
decreased in patient fibroblasts, despite the fact that TIM22
mRNA expression was increased by almost 2-fold (reflecting
either an up-regulation or a decreased degradation of the
mRNA). This suggests that the p.Val33Leu variant destabilizes
the protein, either at a structural level or by interfering with
complex biogenesis, which is likely responsible for the loss of
TIM22 protein. Further analyses of the p.Val33Leu variant are
necessary to assess the effect of this variant on the function of
TIM22 and on the expression of the disease. Furthermore, the
up-regulation of TIM22 provides evidence of a positive feedback
loop, which alters transcription to compensate for protein
loss. The existence of a tight regulatory system highlights the
critical role TIM22 has for mitochondrial homeostasis. The
mechanisms that govern this feedback loop would provide
valuable information regarding the regulation of carrier import.
Defects in metabolite carrier import into mitochondria have
been associated with other forms of Mendelian mitochondrial
disease. Sengers syndrome is a mitochondrial disorder, pre-
senting with congenital cataracts, hypertrophic cardiomyopa-
thy, skeletal myopathy, exercise intolerance, lactic acidosis and
delayed motor development. The disease can manifest in child-
hood or early adult life and has been associated with defects
in the AGK (37). In addition to its role in mitochondrial lipid
metabolism, AGK has recently been shown to be a component of
the TIM22 complex (9,10). However, it is unclear to which extent
the different phenotypes observed manifest because of defects
in carrier transport, lipid metabolism or both. Interestingly, we
observed the same levels of AGK in TIM22mutant mitochondria,
meaning that neither TIM22 nor TIM29 are required for the
stability of AGK. Although some of the TIM22 patient’s symp-
toms may resemble those from Sengers syndrome patients, the
molecular defects that we observed are solely associated with
a carrier import deficiency and not with complementary lipid
metabolism defects through loss of AGK. Moreover, mutations
in DDP1/TIM8A are the cause of Mohr–Tranebjaerg syndrome,
also known as deafness-dystonia syndrome. This is a reces-
sive neurodegenerative disorder characterized by progressive
sensorineural deafness, cortical blindness, dystonia, dysphagia
and paranoia (24). TIM8A forms a hexameric ring, together with
TIM13. The presence of mutations in TIM8A may disrupt forma-
tion of this complex (25). The yeast Tim8-Tim13 complex has
been suggested to participate in the import of Tim23 (38,39).
However, import processes differ between yeast and human
mitochondria and the TIM22 pathway is the most divergent (23).
Therefore, it remains unclear which substrates depend on the
TIM8A-TIM13 complex for import andmore so, how pathological
mutations in TIM8A would affect TIM22 function.
Mutations within single mitochondrial-metabolite carrier
proteins have a strong impact on mitochondrial function and
many have been associated to disease. For example, domi-
nantly inherited mutations in SLC25A4 encoding the ADP/ATP
carrier AAC1 (ANT1) cause adult-onset autosomal dominant
progressive external ophthalmoplegia, associated with multiple
mtDNA deletions, whereas recessive SLC25A4 mutations cause
childhood-onset mitochondrial myopathy and cardiomyopathy
(40); a recent report has also identified de novo dominant SLC25A4
variants, affecting key residues, causing mtDNA depletion.
In addition, mutations in SLC25A24 (ATP-Mg/Pi carrier) cause
Gorlin–Chaudhry–Moss syndrome, a dysmorphic syndrome,
characterized by coronal craniosynostosis and severe midface
hypoplasia, body and facial hypertrichosis, together with
progeroid appearance and mitochondrial dysfunction (41).
Therefore, the identification of a novel mutation in TIM22 is
a key not only for a better understanding of the mechanisms
leading to metabolite carrier import in human mitochondria,
but also to dig further into the pathological roles of the loss of
carrier proteins in mitochondrial disease.
In summary, the process of identifying the molecular defect
underlying the phenotype of this patient nicely illustrates the
inherent complexity and heterogeneity associated with mito-
chondrial diseases. Two very different genomes are involved in
the expression of the mitochondrial proteome and therefore,
potential variants of both genomes need to be assessed for
pathogenicity. In this case, we identified for the first time, com-
pound heterozygous variants in TIM22 in a patient with salient
clinical features of mitochondrial disease. We have shown that
these variants exert a molecular impact on the integrity of the
carrier translocase, and alter the levels of carrier proteins within
mitochondria. This alterationmight cause an imbalance ofmito-
chondrial metabolites and lead to a secondary dysfunction of




Primary fibroblasts were cultured in Dulbecco’s modified Eagle’s
medium (DMEM), supplemented with 10% (v/V) heat-inactivated
fetal bovine serum (Biochrom, Berlin, Germany), 2 mM L-
glutamine, 1 mM sodium pyruvate and 50 μg/ml uridine and
incubated at 37◦C with 5% CO2. Primary fibroblasts were
immortalized using as previously described (42) lung carcinoma
A549 cybrids, generated by fusing platelets containing mito-
chondria andmtDNAwith rho0 cells,were cultured as previously
described (43,44). Growth test experiments were performed by
seeding cells directly in medium where glucose was replaced
by 0.9 g/L of galactose. Cells were counted after 3 days using a
hemocytometer.
For electroporation experiments, immortalized patient
fibroblast cells were grown to 70% confluency. Cells were
harvested,washed in phosphate-buffered saline (PBS) and resus-
pended to a density of 5×107 cells/ml in electroporation buffer,
provided with the NeonTM transfection system kit (Invitrogen,
Germany). Cells were electroporated with a plasmid-containing
wild-type TIM22 (NM 013337) cDNA that had been amplified
from HEK293T cDNA and then cloned into the pcDNA5/FRT/TO
vector (Invitrogen, V6520-20). Plasmid DNA was electroporated
at a final concentration of 250 μg/ml. Electroporation was
performed using the NeonTM Transfection system (Invitrogen)
using the following conditions: pulse number, 2; pulse width,
20; voltage, 1150. Cells were then immediately resuspended in
DMEM medium and incubated at 37◦C with 5% CO2 for at least
48 h.
MtDNA genetic studies
MtDNA sequences were obtained by using previously described
methods (44,45).
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Whole-exome sequencing, variant calling and
bioinformatic filtration
Study participants providedwritten informed consent for exome
sequencing under a protocol approved by the institutional
review board of Scripps. DNA was extracted from freshly
drawn blood and whole exome sequencing (WES) was pursued
utilizing Agilent SureSelect exome hybridization followed by
barcoding and sequencing of paired 100 bp reads on an Illumina
HiSeq2500 instrument. Read mapping and variant calling
and quality filtration was performed using a BWA-GATK best
practices variant quality score recalibration approach. Variant
annotation was performed using the SG-ADVISER system (46).
A series of filters was applied to derive a set of candidate
disease causative variants: [1] population-based filtration was
liberally set at >1.0% allele frequency in the Exome Aggregation
Consortium, 1000 Genomes, National Heart, Lung and Blood
Institute (NHLBI) Exome Sequencing Project or ScrippsWellderly
populations; [2] functional impact-based filtration to remove
variants that are not nonsynonymous, frameshift, inframe,
nonsense or do not affect canonical splice-site donor/acceptor
sites; and [3] inheritance-based filters to remove variants that
do not segregate in the family in a manner consistent with de
novo/recessive manner.
Quantitative PCR
RNA was extracted from control and patient fibroblasts using
TRIzolTM reagent (Invitrogen, Carlsbad, California, USA) as
per the manufacturer’s instructions. cDNA was generated
using the First Strand cDNA Synthesis kit (Thermo Scientific,
Waltham, Massachusetts, USA), with random hexamer primers.
Quantitative real-time PCR was performed in triplicate using
SensiMix SYBR Low-Rox one-step kit and amplification was
carried out in a QuantStudioTM 6 Flex System (Applied
Biosystems, Foster City, California, USA). Primers for ampli-
fication of TIM22 were 5′-CGGGGAACATCAGACTGGAA-3′ and
5′-GCCTTTAAGCCAGCTCTGAAAC-3′ and levels were normal-
ized against HPRT (5′-TGGACAGGACTGAACGTCTT-3′ and 5′-
ACAGTCATAGGAATGGATCTATCA-3′).
Fluorescence microscopy
Fibroblasts were grown on coverslips for at least 24 h. Prior
to fixation, cells were incubated with MitoTracker® Orange
CMTMRos (Life Technologies) for 15 min and then fixed in 4%
paraformaldehyde for 20 min at 37◦C. Cells were washed in
PBS and mounted in histology mounting medium containing
DAPI (FluoroshieldTM; Sigma-Aldrich, St.Louis, Missouri, USA).
Images were taken using a DeltaVision Spectris epifluorescence
microscope (Applied Precision, Issaquah, Washington, USA) at
60× magnification, equipped with a TRITC (excitation 542/27,
emission 594/45) and DAPI (excitation 390/18, emission 435/48)
filter set. Series of 10–15 sections with 0.5 μm spacing along the
Z-axis were taken. Images were deconvoluted and a maximum
projection of the stacks was generated bymerging the individual
slices using the softWORx software (Applied Precision).
Real-time respirometry
OCRwasmeasured with a XF96 Extracellular Flux Analyzer (Sea-
horse Bioscience, Billerica, MA, USA). Fibroblasts were seeded
the day before the measurement at a density of 40.000 cell-
s/well. Baseline respiration was measured in DMEM supple-
mented with 1 mm pyruvate and 25 mm glucose after cali-
bration at 37◦C in an incubator without CO2. Periodic mea-
surements of oxygen consumption were performed and OCR
was calculated from the slope of change in oxygen concen-
tration over time. Metabolic states were measured after subse-
quent addition of 3 μM oligomycin, 1 μM carbonyl cyanide-4-
(trifluoromethoxy)phenylhydrazone, 2 μM antimycin A and 1 μM
rotenone.
Labelling of mitochondrial translation products
In vivo radiolabelling in human immortalized fibroblasts
and A549 cybrids was done as previously described (47).
Cytosolic translation was inhibited with 100 mg/ml emetine
and mitochondrial translation pulsed with 0.2 mCi/ml [35S]-
methionine for 2 h. To visualize radiolabelled proteins, whole-
cell lysates were obtained and analysed by SDS-PAGE and
autoradiography.
Enzymatic activities and ATP levels
A quantitative method enzyme-linked immunosorbent assay
(ELISA) for cytochrome c oxidase specific activity determination
was applied using a protocol described elsewhere (48). Citrate
synthase (CS) specific activity was measured using previously
described protocols (44). For analysis of ATP levels, cells were
washed twice with PBS and incubated for 2 h in record buffer
containing 5 mm 2-Deoxy-D-glucose and 1 mm pyruvate. Cells
were lysed and incubated with luciferin/luciferase reagents (44).
All biochemical measurements were done in a NovoStar MBG
Labtech (Offenburg, Germany) microplate instrument.
Mitochondrial isolation and whole-cell lysis
Mitochondria were isolated by differential centrifugation as pre-
viously described (8). Protein concentration was measured by
Bradford analysis using BSA as a standard.
Human fibroblasts were harvested, pelleted and resuspended
in cell lysis buffer [50 mm Tris-HCl (pH 7.5), 130 mm NaCl,
2 mm MgCl2, 1% Nonidet P-40, 1 mm phenylmethylsulfonyl
fluoride (PMSF) and protease inhibitor cocktail (Pierce,Waltham,
Massachusetts, USA)]. Cell lysates were vortexed briefly and
centrifuged at 8000g for 5 min at 4◦C and the supernatant
retained. Cell lysates were incubated with sample dissociation
buffer [final concentrations: 6.25 mm Tris-HCl (pH 6.8), 2% SDS,
10% glycerol, 0.01% bromophenol blue and 100 mm DTT] for
30 min at 37◦C.
Miscellaneous
For Blue Native PAGE analyses, isolated mitochondria were
solubilized in buffer [0.4% DDM, 20 mm Tris/HCl pH 7.4, 0.1 mm
ethylenediaminetetraacetic acid (EDTA), 50 mm NaCl, 10% (w/v)
glycerol and 1 mm PMSF] to a final concentration of 1 μg/μl
for 20 min at 4◦C. Lysates were cleared by centrifugation at
14 000×g for 10 min at 4◦C and 10× loading dye was added
(5% Coomassie brilliant blue G-250, 500 mm 6-aminohexanoic
acid, 100 mm Bis-Tris, pH 7.0). Samples were loaded onto 6–
16% polyacrylamide gradient gels and separated as previously
described (49). SDS/PAGE and western blotting of proteins
onto polyvinylidene fluoride membranes (Millipore, Burlington,
Massachusetts, USA) was performed using standard methods.
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Primary antibodies were raised in rabbit or purchased (anti
NDUFB8, Abcam, UK; anti SDHB, Abcam; anti UQCRC2, Abcam;
anti COXII, Abcam; anti ATP5A, Abcam; anti β-actin, Cloud-
Clone Corp., Houston, Texas, USA; anti TIM22, Proteintech,
Chicago, Illinois, USA; anti ANT3, Proteintech; anti SDHA,
Cell Signalling, Danvers, Massachusetts, USA; anti β-tubulin,
Abcam). Antigen–antibody complexes were detected using
either HRP-coupled secondary antibodies and enhanced
chemiluminescence detection on X-ray films (GE Healthcare,
Chicago, Illinois, USA), or BioRad, Hercules, California, USA
ChemiDoc MP with Image Lab software, or IRDye® 800CW,
Li-Cor, Lincoln, Nebraska, USA and detection at 800 nm on a
FLA-9000 (Fujifilm, Japan).
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